Download PDF
Thromb Haemost 1993; 70(01): 094-098
DOI: 10.1055/s-0038-1646167
State-of-the-Art Lecture
Plateley Receptors
Schattauer GmbH Stuttgart

Clinical Trials of Platelet Receptor Inhibitors

Eric J Topol
Center for Thrombosis and Vascular Biology, Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH, USA
,
Edward F Plow
Center for Thrombosis and Vascular Biology, Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
03 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Plow EF, Ginsberg MH. Cellular adhesion: GPIIb/IIIa as a prototypic adhesion receptor. Prog Hemostas Thromb 1988; 296: 320-331
    PubMedGoogle Scholar
  • 2 Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988; 71: 831-843
    CrossrefPubMedGoogle Scholar
  • 3 Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42
    CrossrefPubMedGoogle Scholar
  • 4 Bellinger DA, Nichols TC, Read MS, Reddick RL, Lamb MA, Brinkhous KM, Evatt BL, Griggs TR. Prevention of occlusive coronary artery thrombolysis by a murine monoclonal antibody to porcine von Willebrand factor. Proc Natl Acad Sci USA 1987; 84: 8100-8104
    CrossrefPubMedGoogle Scholar
  • 5 Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101-108
    CrossrefPubMedGoogle Scholar
  • 6 Coller BS, Scudder E, Berger HJ, Iuliucci JD. Inhibition of human platelet function in vivo with a monoclonal antibody: with observations on the newly dead as experimental subjects. Ann Intern Med 1988; 109: 635-638
    CrossrefPubMedGoogle Scholar
  • 7 Jordan RE, Knight DM, Wagner C, McAleer MF, McDonough M, Mattis JA, Coller BS, Weisman HF, Ghrayeb J. A dramatic reduction of the immunogenicity of the anti-GPIIb/IIIa monoclonal antibody, 7E3 Fab, by humanization of the murine constant domains. Circulation 1992; 86 (Suppl. I) I-410 (abstr.)
    PubMedGoogle Scholar
  • 8 Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, Jordan R, Berger H, Collen D, Coller BS. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651-659
    CrossrefPubMedGoogle Scholar
  • 9 Simoons ML. on behalf of the European Cooperative Study Group. Randomized trial of monoclonal platelet antibody for refractory unstable angina pectoris. Presented at the European Congress of Cardiology; Barcelona, Spain, September: 1992
    Google Scholar
  • 10 Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D. et a!.: A monoclonal antibody against the platelet GPIIb/IIIa receptor prevents coronary artery reocclusion following reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988; 81: 1284-1291
    CrossrefPubMedGoogle Scholar
  • 11 Mickelson JK, Simpson PJ, Lucchesi BR. Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 1989; 21: 393-405
    CrossrefPubMedGoogle Scholar
  • 12 Kleiman NS, Ohman ME, Califf RM, George BS, Kereiakes D, Aguirre F, Bates E, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab following thrombolytic therapy: Results or the TAMI 8 Pilot Study. J Am Coll Cardiol. 1993 in press
    PubMedGoogle Scholar
  • 13 Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA. et al.: Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-1719
    CrossrefPubMedGoogle Scholar
  • 14 Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic, and therapeutic profile. J Am Coll Cardiol 1992; 19: 926-935
    CrossrefPubMedGoogle Scholar
  • 15 Simpfendorfer C, Belardi J, Bellamy G, Galan K, Franco I, Hollman J. Frequency, management and follow-up of patients with acute occlusions after percutaneous transluminal coronary angioplasty. Am J Cardiol 1987; 59: 267-269
    CrossrefPubMedGoogle Scholar
  • 16 Ellis SG, Tcheng JE, Navetta FI, Muller DW, Weisman HF, Smith C, Anderson KM, Califf RM, Topol EJ. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coronary Artery Dis 1993; 4: 167-176
    CrossrefPubMedGoogle Scholar
  • 17 Tcheng JE, Kleiman NS, Miller MJ, Sane DS, Wang AL, Weisman HF. Chimeric antiplatelet GPIIb/IIIa receptor antibody (C-7E3) in elective PTCA: safety and platelet function inhibition. Circulation 1992; 84 (Suppl. II) II-590 (abstr.)
    PubMedGoogle Scholar
  • 18 Bernardi MM, Califf RM, Kleiman N, Ellis SG, Topol EJ. for the TAMI Study Group. Prolonged bleeding times do not predict hemorrhagic events in patients receiving the 7E3 glycoprotein (Ib/IIIa platelet antibody. Circulation 1992; 86 (Suppl. I) I-260 (abstr.)
    PubMedGoogle Scholar